Diffuse gliomas are tumors that affect the brain and spinal cord. Gliomas that develop in people with mutations in IDH1 and IDH2 genes are especially aggressive. A clinical trial led by Jing Wu, M.D., Ph.D., Lasker Clinical Research Scholar in the Neuro-Oncology Branch, is researching a drug therapy for these tumors. The trial will take place at the NIH Clinical Center in Bethesda, Maryland, and there is no cost for participation.
For more information, contact Kelly Mentges at email@example.com or the NCI NOB Referral Group at 866-251-9686.
Clinicaltrials.gov identifier: NCT05588141
NCI Protocol ID: 000860
Official Title: A Phase I/II Study of Zotiraciclib for Recurrent High-Grade Gliomas With Isocitrate Dehydrogenase 1 or 2 (IDH1 or IDH2) Mutations
The Center for Cancer Research is NCI’s internal cancer center, a publicly funded organization working to improve the lives of cancer patients by solving important, challenging and neglected problems in cancer research and patient care. Highly trained physician-scientists develop and carry out clinical trials to create the medicines of tomorrow treating patients at the world’s largest dedicated research hospital on the campus of the National Institutes of Health in Bethesda, Maryland.
For more information on CCR clinical trials click here, and subscribe to have the latest CCR clinical trials sent directly to your inbox.